SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: semi_infinite who wrote (891)7/20/2018 4:00:10 PM
From: tuck  Read Replies (1) of 897
 
No, SYRS was right there:
Syros failed with its patient enrichment strategy. It hasn't recovered as well, but since Jounce failed with a similar strategy, SYRS has floated along . . .
And I still hold a short position in it, having made modest money on a prior one.

Anyhow, MRTX is a TKI company. I haven't dug hard, but one of the three candidates in early development that I'm aware of is sitravatinib. It has shown some signs of cardiotox as monotherapy, and is being tried in combo with nivolumab in a couple of different indications. Nivolumab has its own cardiotox signal. There should be interim and final readouts in coming months and years. A safety fail wouldn't tank the company, but would ding it, considering the expectations now built in to it.

Then there's this list of setbacks from AndyBiotech:

http://Mirati

Apparently, today's rise was on the back of a couple of price target raises into the $60s.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News